NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: NICE's radical diabetes prescribing transformation, EU device JCAs launching, and FDA's accelerated approval surge. Let's get into it.

SaraThe February 2026 NICE NG28 update is the biggest diabetes prescribing shift we've seen. SGLT-2 inhibitors are now first-line therapy with metformin for all Type 2 diabetes patients, regardless of comorbidities. NICE projects 17,000 deaths prevented over three years.

MarcusThis is evidence-driven prescribing at its best. Moving from glycemic control primacy to cardiovascular and renal protection makes clinical sense. Seven tailored pathways for specific comorbidities—early-onset diabetes, heart failure, chronic kidney disease, frailty. The evidence base for SGLT-2 cardioprotection is rock solid.

SaraBut Marcus, this is also a massive commercial restructuring disguised as clinical guidance. We're essentially mandating dual therapy as standard, doubling drug spend per patient from day one. Yes, the long-term outcomes look favorable, but the budget impact modeling here must be extraordinary.

MarcusYou're focusing on acquisition cost, not total cost of care. If we prevent 17,000 deaths, we're also preventing hundreds of thousands of hospitalizations, dialysis initiations, amputations. The downstream savings dwarf the upfront drug costs.

SaraThat's assuming perfect adherence and real-world effectiveness matching trial data. We're extrapolating trial populations to entire Type 2 diabetes cohorts. The health economic modeling is aggressive.

MarcusMoving to the EU HTA Regulation's device expansion. June 2026 brings the first JCAs for Class IIb and III devices plus Class D IVDs. Approximately 50 JCAs for medicines plus 5 device JCAs in the 2026 Work Programme.

SaraThe operational constraints are already showing. Joint Scientific Consultation slots capped at 17 for 2026—8-12 for medicines, 2-5 for devices. Demand exceeds capacity before we've even hit steady state. This is rationing scientific advice.

MarcusIt's capacity planning reality. The European Commission is managing a staged rollout rather than overwhelming the system. Better controlled expansion than collapse under demand.

SaraBut we're creating artificial scarcity in scientific advice just as device manufacturers need guidance most. The first device JCAs will set precedents for methodology, assessment scope, clinical endpoints. Limited consultation access at this critical juncture is strategically problematic.

MarcusThe EU clinical trial progress report shows tangible acceleration. Nineteen additional multinational trials beyond historical averages, 40.5% recruiting within 200 days toward the 66% target by 2030.

SaraEarly momentum, but let's be realistic about the trajectory. We need 500 extra trials by 2030. Nineteen additional in Q1 puts us well behind the linear progression needed. And 40.5% recruitment within 200 days is still under half of trials meeting reasonable timelines.

MarcusYou're expecting linear progress on a transformation that requires infrastructure changes, regulatory harmonization, investigator training. Early indicators matter more than absolute numbers.

SaraFinally, May 2026's FDA accelerated approvals deserve attention. Sonrotoclax for mantle cell lymphoma, all-oral AML regimen with decitabine/cedazuridine plus venetoclax, vepdegestrant for ESR1-mutated breast cancer. Plus the June 2nd draft guidance accelerating cell and gene therapies.

MarcusThe FDA is clearly committed to expedited pathways for innovation. But accelerated approvals create downstream HTA challenges. Payers need robust evidence for coverage decisions, and accelerated pathways often mean limited real-world data at launch.

SaraExactly the tension we're seeing globally. Regulatory speed versus HTA evidence requirements. The FDA can accelerate based on surrogate endpoints, but payers want overall survival and quality of life data that takes years to mature.

MarcusThree major themes this week: evidence-based prescribing transformation, operational scaling challenges, and the persistent tension between regulatory speed and HTA evidence depth.

SaraPlus the reality that every policy change—whether NICE guidelines or EU device JCAs—creates winners and losers in the commercial landscape. The evidence informs, but doesn't eliminate, the strategic implications.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.